Zoetis logo

Zoetis Receives Approval For Lenivia® (izenivetmab) In Great Britain

3 hours ago
73 views

Posted
1st June, 2026 16h26

Author
Zoetis

Zoetis UK Ltd. announced that the UK’s Veterinary Medicines Directorate (VMD) has approved Lenivia^® (izenivetmab injection) for the alleviation of pain associated with osteoarthritis in dogs. Backed by a decade of science and research, Lenivia is a new antibody therapy that, in a field study, showed dogs receiving it experienced improved mobility and reduced pain after a single injection. Lenivia offers effective alleviation from pain associated with osteoarthritis for up to three months with a single injection, acting via its novel binding to nerve growth factor (NGF), a recognised mediator of pain and inflammation.

“Lenivia’s approval marks a meaningful milestone in our continued innovation for canine osteoarthritis pain,” said Julia von Gablenz, Regional President, Europe & Middle East of Zoetis. “Dogs with osteoarthritis can experience persistent pain that affects comfort, mobility, and quality of life. With Lenivia’s approval, we’re proud to bring UK(GB) veterinary professionals a new, long-acting option that can help alleviate osteoarthritis-associated pain and support sustained comfort with a single injection.”

Significance of Osteoarthritis Pain

Osteoarthritis is a common, chronic and progressive joint disease characterised by the inflammation and breakdown of joints, leading to pain and mobility issues. Although the disease cannot be cured, much can be done to alleviate the associated pain and help improve quality of life. Nearly 40 percent of dogs of any age or size may be affected by osteoarthritis pain^{1, 2}, and chronic pain can negatively impact dogs’ movement, sleep, behavior and social relationships³.

Continued Innovation to Meet Medical Needs

Zoetis continues to advance care for animals around the globe with a robust pipeline fueled by lifecycle innovation, geographic expansion and new innovation. Lenivia builds on Zoetis’ established portfolio, backed by extensive scientific research in veterinary monoclonal antibodies.

By offering a long-acting injectable option, Lenivia is indicated to help alleviate pain associated with osteoarthritis as part of an individualised management plan developed by the veterinary professional. Lenivia should be used under the guidance of a veterinary professional and in accordance with the approved GB product information.

¹ Wright A, Amodie DM, Cernicchiaro N, et al. Identification of canine osteoarthritis using an owner-reported questionnaire and treatment monitoring using functional mobility tests. J Small Anim Pract. 2022;63(8):609-618.
² Enomoto M, de Castro N, Hash J, et al. Prevalence of radiographic appendicular osteoarthritis and associated clinical signs in young dogs. Sci Rep. 2024;14(1):2827.
³ Lascelles BDX, Brown DC, Conzemius MG, Gill M, Oshinsky ML, Sharkey ML. Measurement of chronic pain in companion animals: discussions from the Pain in Animals Workshop (PAW) 2017. Vet J. 2019;250:71-78.

More from Zoetis

• Equine Vets Invited to Build Communication Confidence and Clinical Influence
• Zoetis Expands Vetscan OptiCell™ Capabilities, Becoming the First and Only Haematology Analyser to Bring Reference Lab Insights In-Clinic
• Zoetis officially partners with Cats Protection
• Vets encouraged to talk to farmers about season long worm and fly control in cattle
• Zoetis renews partnership with BVNA